Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Next Previous
Trial Profile

Allogeneic Hematopoietic Stem Cell Transplantation For The Treatment Of High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Busulfan (Primary) ; Fludarabine (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use

Most Recent Events

  • 24 Aug 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 08 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
  • 02 Sep 2010 Planned end date changed from 1 Sep 2011 to 1 Sep 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top